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received an added benefit, in France all drugs assessed received a positive SMR 
and no improvement in actual benefit.
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Objectives: To evaluate the prevalence and patterns of CAM use among dia-
betes patients in Pakistan. In addition, the study also focused on the perceived 
effectiveness of CAM over conventional therapies, information seeking behavior 
and CAM disclosure to healthcare providers. MethOds: A prospective, cross-
sectional and self-administered questionnaire based study was conducted in 
tertiary care public hospitals in Pakistan. A prevalence based sample of 350 dia-
betes patients attending the tertiary hospital in Punjab, Pakistan were selected 
for the study. All obtained data were analyzed using descriptive and inferential 
statistics. Results: Overall, 327 questionnaires were completed and included in 
the analysis, showing that 52.8% of diabetics had used CAM, with most (62.4%) 
believing that CAM therapies assist body’s natural forces to heal. CAM usage 
was significantly associated with gender (P= 0.001), level of education (P= 0.001), 
employment status (P= 0.03) and monthly income (P< 0.001). cOnclusiOns: 
Diabetes treatment and management requires compliance to effective therapies 
at early stages. Healthcare providers should engage diabetics in an open non-judg-
mental dialogue to ascertain better understanding of diabetes and its management 
options.
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Objectives: Since 2011, an early benefit assessment is required for all new drugs 
being launched in Germany. Evidence submitted by pharmaceutical companies 
in dossiers is assessed by the Institute for Quality and Efficiency in Health Care 
(IQWiG) and subsequently appraised by the German Federal Joint Committee (FJC). 
The exact determination of the patient target population plays an important role 
for subsequent price negotiations. In diabetes mellitus type 2 the size of target 
population varies considerably between dossiers. Our aim was to explore the 
reasons for these differences. MethOds: We analyzed 20 dossiers with drugs for 
diabetes mellitus type 2 published between January 2012 and May 2015. Details 
regarding the estimation of the target population were extracted and compared. 
Based on the extractions a criteria list was developed to categorize possible rea-
sons for different sizes of the target population. Results: The estimations of the 
target population were mainly based on secondary data analyses of drug prescrip-
tions. The methods and assumptions used to analyze these data varied widely. 
Important reasons for differences in the estimations are the kind of database, the 
time frame, the operationalization of diabetes patients, the specification of the 
target population, the type of contraindications, the consideration of currently 
undetected patients, the mode of extrapolation to the overall population, and the 
portion of statutory health insurance patients. We could not identify one reason 
that could explain most of the deviations in the size of the target population. 
Several reasons seem to interact and it was not possible to determine the direc-
tion or size of the effect. cOnclusiOns: There is a strong need for more detailed 
descriptions of the methods and databases used in the dossiers to estimate the 
size of the target populations. A harmonization of the methods seems to be help-
ful to reduce the variation.
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Objectives: Modifiable risk factors such as trio Hs are major contributor to the 
disease burden in Malaysia. Heart disease is number one leading cause of death 
in the country and individuals with diabetes are two to four times more likely 
to develop heart disease or stroke relative to those without diabetes. In view of 
severe multifold outcome caused by trio Hs, we aim to examine the prevalence of 
undiagnosed trio Hs and management of these risk factors among participants 
who had previously detected with these conditions. MethOds: We retrospec-
tively performed secondary data analysis on random selective samples from 
Pfizer Care-a-Van community health screening which was established in year 
1999. Health screenings were conducted in mobile examination centers across 
the country by a team of registered physician, nurses, and volunteers along with 
various NGO partners. Standardized screening forms were used to collect demo-
graphic data and screening results. Participants with abnormal screening results 
will be referred to government clinics or hospitals for further tests and/or treat-
ment. Descriptive analysis was performed using Stata 13. Results: A total of 
7601 subjects were available for analysis from 2003 till 2014. Over half (58.4%) of 
the screening participants were female aged 45.8 years (SD, 14.4). 13.3% had been 
previously diagnosed with hyperlipidemia, while 10.6% and 13.1% were diabetic 
and hypertensive. Undiagnosed hyperlipidemia was reported at 56.5%, followed 
by hyperglycemia (32.5%) and hypertension (17.8%). Almost half (49.9%) of hyper-
tensive and 59.2% hyperlipidemia subjects failed to achieve target blood pres-
sure and cholesterol level whereas only 38.2% diabetic had their blood glucose 
under control. cOnclusiOns: Multiple risk factors pose a significant burden 
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Objectives: The aim of this study was to assess the burden of peripheral arte-
riopathy (PA) in diabetic patients. MethOds: Eligible patients were identified 
through a data warehouse (DENALI), which matches clinical and economic data 
of about 9.9 million individuals of Lombardy, a northern Italian region which 
represent 16.4% of the Italian population. The study population was made of all 
individuals over 40 with a diagnosis of diabetes who during the period 1-1-2002 
to 31-12-2009 had an hospital admission (index event) attributable to PA disease. 
The identified individuals were followed-up from the index event to a maximum 
of 7 years. We evaluated demographic characteristics of the study population 
and costs (hospitalizations, drugs and outpatient examinations/visits) from the 
National Health Service’s perspective. Results: During the observational period 
18,344 subjects (5% of the diabetic source population) had at least one hospital 
admission of interest. Median age (min-max) at the index date was 73(40-102) 
and 31% of the study population had a Charlson comorbidity index higher than 3. 
The overall mortality was 11.3 deaths every 100 patient-years (95%C.I., 11.1-11.6). 
Forty-four percent of the study population had at least one procedure among 
vascularization, minor and major amputation. Mean cost and corresponding 95% 
C.I. (€ /patient-year) for PA diabetic patients was 14,085(12,344-16,400) in the index 
year and around 7,000 in the following periods of observation. Hospitalizations 
represented the driver of total costs. cOnclusiOns: This study attempted to 
describe the epidemiologic and economic burden of diabetes patients with PA 
complications, showing the relevance of related epidemiologic and economic 
aspects.
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Objectives: Dipeptidyl peptidase-4 (DPP-4) inhibitors were recently approved 
in the US. The objective is to evaluate the prescribing behavior of traditionally 
used type 2 diabetic medications and the newer DPP-4 inhibitors. MethOds: 
This cross-sectional study used data from the 2006-2010 National Ambulatory 
Medical Care Survey (NAMCS) and employed the Eisenberg model of physi-
cian decision making. The dependent variable was the use of DPP-4 inhibitors. 
The following independent variables were determined based on the Eisenberg 
model: age, gender, race/ethnicity, insurance type, primary care physician, 
practice region, metropolitan status, practice setting, previous physician office 
visits, and the type of diabetes medication, and survey year. Multivariate logis-
tic regressions were used for analyses. Results: The estimated population 
size was 535,158,796 patients with type 2 diabetes, and 3.85% of them were 
prescribed DPP-4 inhibitors. The most frequently used diabetic medication 
group was biguanides (metformin) (26.1%), followed by sulfonylurea (17.8%). 
The use of other diabetes medication was highly associated with the likelihood 
of the use of DPP-4 inhibitors. Patients who were prescribed sulfonylurea were 
approximately twice and patients who were prescribed biguanides (metformin) 
were approximately three times more likely to be prescribed DPP-4 inhibitors 
(OR = 1.62; p = 0.009 and OR = 2.96; p < 0.001, respectively). The likelihood of 
the use of DPP-4 inhibitors was also increased with patients receiving insulin 
(OR = 1.62; p = 0.009). cOnclusiOns: The prescribing of the DPP-4 inhibi-
tors increased with current use of biguanides (metformin), sulfonylureas, and 
insulin.
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Objectives: In recent years new type II diabetes (T2D) therapies were launched 
and evaluated by the different market access authorities in France and Germany. 
Decisions were mostly controverse especially in Germany why a comparison 
with comparable health care systems is required. The international Prismaccess 
database includes all evaluations and decisions in France and Germany, besides 
other global authorities. MethOds: All decisions for new T2D therapies in 2014 
and 2015 which were evaluated by the authorities in France and Germany were 
systematically searched for. A comparison was executed with a focus on reim-
bursement decision, basis of decision, acceptance of submitted clinical endpoints, 
study designs, and comparators. Results: In total there were 9 new therapies 
evaluated in France by the Transparency Commission. The level of added benefit 
differed mainly dependent on the combination or monotherapy analyses with 
other OADs and/or insulin. Five out of 9 drugs had all anti-diabetic drugs as com-
parators without specific distinction and 8 out of 9 drugs were rated with an ASMR 
versus the therapeutic strategy. Even though that all therapies received a substan-
tial SMR, most also had some insufficient ratings with respect to monotherapy. All 
therapies received an ASMR rating of V (no added benefit). In Germany the G-BA 
evaluated seven drugs. Six therapies received a non-added benefit. Albiglutide 
was the only therapy receiving an added benefit (non-quantifiable benefit). All 
comparators were against other active diabetes drugs. One exception was the 
assessment of canagliflozin in combination with metformin which was not only 
compared against drugs but against therapeutic strategies. cOnclusiOns: Using 
the Prismaccess database the analysis shows that there are key differences in 
the assessment of the same clinical data in T2D. In Germany only one therapy 
